Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% above fair value
$0.82+0.02 (+2.60%)
Close on Nov 17, 2026Market cap $206.32MP/E –Yield –
Lineage Cell Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Lineage Cell Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $20.52M, up 60.1% year over year. For fiscal 2025 it was $17.73M, up 42.2% from the year before. Over ten years it grew -8.4% a year on average. The highest annual figure on record is $42.60M in fiscal 2015.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.73M | +42.2% |
| FY2024 | Dec 31, 2024 | $12.47M | -20.6% |
| FY2023 | Dec 31, 2023 | $15.71M | +12.3% |
| FY2022 | Dec 31, 2022 | $13.99M | -58.8% |
| FY2021 | Dec 31, 2021 | $33.91M | +175.3% |
| FY2020 | Dec 31, 2020 | $12.32M | -31.4% |
| FY2019 | Dec 31, 2019 | $17.95M | -14.3% |
| FY2018 | Dec 31, 2018 | $20.96M | -12.8% |
| FY2017 | Dec 31, 2017 | $24.02M | -33.5% |
| FY2016 | Dec 31, 2016 | $36.11M | -15.3% |
| FY2015 | Dec 31, 2015 | $42.60M | +13.5% |
| FY2014 | Dec 31, 2014 | $37.53M | +41.1% |
| FY2013 | Dec 31, 2013 | $26.61M | +46.9% |
| FY2012 | Dec 31, 2012 | $18.12M | +32.2% |
| FY2011 | Dec 31, 2011 | $13.70M | +67.2% |
| FY2010 | Dec 31, 2010 | $8.19M | – |
| FY2009 | Dec 31, 2009 | -$3.18M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.77M | +53.7% |
| Q1 FY2026 | Mar 31, 2026 | $4.23M | +36.0% |
| Q4 FY2025 | Dec 31, 2025 | $8.24M | +140.7% |
| Q3 FY2025 | Sep 30, 2025 | $3.27M | +3.2% |
| Q2 FY2025 | Jun 30, 2025 | $3.11M | +8.3% |
| Q1 FY2025 | Mar 31, 2025 | $3.11M | +3.5% |
| Q4 FY2024 | Dec 31, 2024 | $3.42M | -12.4% |
| Q3 FY2024 | Sep 30, 2024 | $3.17M | -15.2% |
| Q2 FY2024 | Jun 30, 2024 | $2.87M | -25.9% |
| Q1 FY2024 | Mar 31, 2024 | $3.01M | -28.1% |
| Q4 FY2023 | Dec 31, 2023 | $3.91M | -4.8% |
| Q3 FY2023 | Sep 30, 2023 | $3.74M | +4.1% |
| Q2 FY2023 | Jun 30, 2023 | $3.87M | +17.3% |
| Q1 FY2023 | Mar 31, 2023 | $4.19M | +40.1% |
| Q4 FY2022 | Dec 31, 2022 | $4.10M | -83.4% |
| Q3 FY2022 | Sep 30, 2022 | $3.59M | +27.8% |
| Q2 FY2022 | Jun 30, 2022 | $3.30M | +12.7% |
| Q1 FY2022 | Mar 31, 2022 | $2.99M | -12.0% |
| Q4 FY2021 | Dec 31, 2021 | $24.78M | +850.4% |
| Q3 FY2021 | Sep 30, 2021 | $2.81M | -21.2% |
| Q2 FY2021 | Jun 30, 2021 | $2.93M | +4.5% |
| Q1 FY2021 | Mar 31, 2021 | $3.39M | +1.6% |
| Q4 FY2020 | Dec 31, 2020 | $2.61M | -25.2% |
| Q3 FY2020 | Sep 30, 2020 | $3.57M | -16.4% |
| Q2 FY2020 | Jun 30, 2020 | $2.81M | -46.4% |
| Q1 FY2020 | Mar 31, 2020 | $3.34M | -32.7% |
| Q4 FY2019 | Dec 31, 2019 | $3.49M | -7.8% |
| Q3 FY2019 | Sep 30, 2019 | $4.27M | -12.6% |
| Q2 FY2019 | Jun 30, 2019 | $5.24M | -17.7% |
| Q1 FY2019 | Mar 31, 2019 | $4.96M | -16.4% |
| Q4 FY2018 | Dec 31, 2018 | $3.78M | -19.5% |
| Q3 FY2018 | Sep 30, 2018 | $4.88M | -25.6% |
| Q2 FY2018 | Jun 30, 2018 | $6.36M | +1.4% |
| Q1 FY2018 | Mar 31, 2018 | $5.94M | -8.6% |
| Q4 FY2017 | Dec 31, 2017 | $4.70M | -33.0% |
| Q3 FY2017 | Sep 30, 2017 | $6.56M | +2.2% |
| Q2 FY2017 | Jun 30, 2017 | $6.27M | – |
| Q1 FY2017 | Mar 31, 2017 | $6.49M | – |
| Q4 FY2016 | Dec 31, 2016 | $7.01M | – |
| Q3 FY2016 | Sep 30, 2016 | $6.42M | – |
See a number that looks wrong?